Piperidines
Medchemexpress LLC (S,R)-GSK321 | 1816272-18-0 | 98.6% | 100 MG
(S,R)-GSK321 is the (S,R)-enantiomer of GSK321. It is a potent, selective mutant IDH1 inhibitor with IC50 values for R132G, R132C, R132H, and WT IDH1, and exhibits >100-fold selectivity over IDH2. (S,R)-GSK321 induces a decrease in intracellular 2-HG, abrogation of the myeloid differentiation block, and induction of granulocytic differentiation. It can be used for research of acute myeloid leukemia (AML) and other cancers.
- Potent, selective mutant IDH1 inhibitor
- Induces a decrease in intracellular 2-HG
- Abrogation of myeloid differentiation block
- Induction of granulocytic differentiation
- Useful in research for acute myeloid leukemia (AML) and other cancers
- Store powder at -20°C for 3 years or 4°C for 2 years
- Store in solvent at -80°C for 6 months or -20°C for 1 month
Medchemexpress LLC (S,R)-GSK321 | 1816272-18-0 | 98.6% | 10 MG
(S,R)-GSK321 is a potent and selective mutant IDH1 inhibitor, specifically the (S,R)-enantiomer of GSK321. It demonstrates high selectivity over IDH2 and induces a decrease in intracellular 2-HG. This compound abrogates the myeloid differentiation block and promotes granulocytic differentiation in leukemic blasts and immature stem-like cells. It is suitable for research into acute myeloid leukemia (AML) and other cancers.
- Potent, selective mutant IDH1 inhibitor
- IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively
- Greater than 100-fold selectivity over IDH2
- Induces a decrease in intracellular 2-HG
- Abrogates the myeloid differentiation block
- Induces granulocytic differentiation in leukemic blasts and immature stem-like cells
- Used for research of acute myeloid leukemia (AML) and other cancers
Medchemexpress LLC (S,R)-GSK321 | 1816272-18-0 | 98.6% | 50 MG
(S,R)-GSK321 is the (S,R)-enantiomer of GSK321, a potent and selective mutant IDH1 inhibitor with strong activity against various mutant IDH1 forms and high selectivity over IDH2. It induces a decrease in intracellular 2-HG, helps abrogate myeloid differentiation block, and promotes granulocytic differentiation in leukemic blasts and more immature stem-like cells. This compound is intended for research use in studies related to acute myeloid leukemia (AML) and other cancers, and is not sold to patients.
- Potent and selective mutant IDH1 inhibitor
- High selectivity over IDH2
- Induces a decrease in intracellular 2-HG
- Abrogates myeloid differentiation block
- Induces granulocytic differentiation
- Suitable for research on acute myeloid leukemia (AML) and other cancers
- Molecular weight: 501.55
- Chemical formula: C28H28FN5O3
- Appearance: white to off-white solid
eMolecules 4-(1-Azepanyl)aniline | 57356-18-0 | MFCD01536453 | 1g
Oakwood Chemical | 4-(1-Azepanyl)aniline | 1g | 537689937 | 038885 | | 57356-18-0 | MFCD01536453 | 190.290 | C12H18N2
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Medchemexpress LLC (S,R)-GSK321 | 1816272-18-0 | 98.6% | 501.55 g/mol | C28H28FN5O3 | 5 MG
(S,R)-GSK321 is the (S,R)-enantiomer of GSK321, a potent and selective mutant isocitrate dehydrogenase 1 (IDH1) inhibitor used as a research tool to study IDH1-driven oncogenic metabolism and differentiation. It reduces intracellular 2-hydroxyglutarate (2-HG) levels and promotes granulocytic differentiation in leukemic cells, supporting studies in acute myeloid leukemia and related cancers.
- Potent mutant IDH1 inhibitor with nanomolar activity.
- Reduces intracellular 2-hydroxyglutarate (2-HG) levels.
- Promotes granulocytic differentiation in leukemic cells.
- High purity suitable for research applications (98.6%).
- Molecular weight 501.55 g/mol; molecular formula C28H28FN5O3.
- Available in small research pack sizes, including 5 mg.